Department of Respiratory and Critical Care Medicine, and Ludwig Boltzmann Institute of COPD and Respiratory Epidemiology, Otto-Wagner-Spital, Sanatoriumstrasse 2, 1140 Vienna, Austria.
Institute of Pathology and Bacteriology, Otto Wagner Hospital, Baumgartner Höhe 1, A-1140 Vienna, Austria, Otto-Wagner-Spital, Sanatoriumstrasse 2, 1140 Vienna, Austria.
Lung Cancer. 2017 Nov;113:4-6. doi: 10.1016/j.lungcan.2017.08.020. Epub 2017 Aug 31.
In the setting of pseudo-progression in a cancer patient who receives immunotherapeutic treatment, discontinuation of therapy is recommended if the patient is symptomatic. Here, we present two patients with advanced adenocarcinoma of the lung who developed massive tumor growth after initiation of treatment with the anti-PD-1 antibody pembrolizumab. Even though clinical deterioration occurred in the form of severe dyspnea and weight loss, pembrolizumab therapy was continued, as the speed of tumor growth suggested pseudo-progression and the tumors showed marked PD-L1 expression. This approach was successful, and both patients experienced impressive treatment responses within a few weeks.
在接受免疫治疗的癌症患者中出现假性进展的情况下，如果患者有症状，建议停止治疗。在这里，我们介绍了两名患有晚期肺腺癌的患者，他们在开始使用抗 PD-1 抗体 pembrolizumab 治疗后出现了大量肿瘤生长。尽管以严重呼吸困难和体重减轻的形式出现了临床恶化，但仍继续使用 pembrolizumab 治疗，因为肿瘤生长速度表明是假性进展，并且肿瘤显示出明显的 PD-L1 表达。这种方法是成功的，两名患者在几周内都经历了令人印象深刻的治疗反应。
